News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,269 Results
Type
Article (19786)
Company Profile (128)
Press Release (310355)
Section
Business (105271)
Career Advice (876)
Deals (18519)
Drug Delivery (93)
Drug Development (50704)
Employer Resources (79)
FDA (7662)
Job Trends (7728)
News (185677)
Policy (17315)
Tag
Academia (726)
Alliances (27792)
Alzheimer's disease (598)
Antibody-drug conjugate (ADC) (71)
Approvals (7646)
Artificial intelligence (106)
Bankruptcy (171)
Best Places to Work (5543)
Biosimilars (74)
Breast cancer (93)
Cancer (816)
Cardiovascular disease (79)
Career advice (708)
Cell therapy (122)
Clinical research (42222)
Collaboration (354)
Compensation (115)
COVID-19 (1086)
C-suite (94)
Data (830)
Diabetes (115)
Diagnostics (1763)
Drug pricing (101)
Earnings (38421)
Employer resources (73)
Events (48035)
Executive appointments (336)
FDA (8063)
Funding (236)
Gene therapy (108)
GLP-1 (534)
Government (1813)
Healthcare (5880)
Infectious disease (1147)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7346)
Job creations (2432)
Job search strategy (646)
Layoffs (262)
Legal (4094)
Lung cancer (128)
Manufacturing (158)
Medical device (1955)
Medtech (1958)
Mergers & acquisitions (11326)
Metabolic disorders (399)
Neuroscience (837)
NextGen: Class of 2025 (2354)
Non-profit (905)
Northern California (854)
Obesity (254)
Opinion (182)
Patents (93)
People (33176)
Pharmaceutical (74)
Phase I (13205)
Phase II (17865)
Phase III (14358)
Pipeline (406)
Policy (83)
Postmarket research (1618)
Preclinical (4597)
Radiopharmaceuticals (158)
Rare diseases (192)
Real estate (3167)
Regulatory (12309)
Research institute (816)
Resumes & cover letters (138)
Southern California (791)
Startups (2006)
United States (7917)
Vaccines (233)
Weight loss (211)
Date
Today (76)
Last 7 days (342)
Last 30 days (1465)
Last 365 days (17492)
2025 (1522)
2024 (17669)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24872)
2019 (20058)
2018 (15587)
2017 (17253)
2016 (16203)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24671)
Australia (3180)
California (1970)
Canada (917)
China (231)
Colorado (81)
Connecticut (77)
Europe (50901)
Florida (318)
Illinois (200)
Indiana (144)
Japan (85)
Maryland (293)
Massachusetts (1659)
Minnesota (111)
New Jersey (770)
New York (577)
North Carolina (417)
Northern California (854)
Ohio (71)
Pennsylvania (461)
South America (605)
Southern California (791)
Texas (257)
Washington State (173)
330,269 Results for "recce pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
January 23, 2025
·
5 min read
Press Releases
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
November 27, 2024
·
3 min read
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.
June 20, 2024
·
3 min read
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Drug Development
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Recce Pharmaceuticals Ltd today announced it received Human Research Ethics Committee (HREC) approval to commence a Phase II trial assessing its lead candidate, RECCE® 327 (R327), as a topical, broad-spectrum gel for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
June 25, 2024
·
4 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
Drug Development
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327
Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II trial for urinary tract infections (UTIs) and urosepsis, demonstrating that its lead candidate, RECCE® 327 (R327), administered intravenously is safe and efficacious against Escherichia coli (E. coli).
July 1, 2024
·
5 min read
Press Releases
Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
December 10, 2024
·
5 min read
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
April 4, 2024
·
4 min read
Press Releases
Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
November 13, 2024
·
5 min read
1 of 33,027
Next
